NCT01270711

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 22,014 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline. Specific objectives will be to assess: 1. The indication for use of cabergoline (Parkinson, hyperprolactinemia, other) 2. Prior treatment strategies in patients who start cabergoline treatment for Parkinson's Disease 3. The percentage of cabergoline users who are prescribed doses above 3 mg per day 4. Whether cabergoline users are monitored by echocardiography prior and during treatment. 5. The incidence and prevalence of valvular fibrosis

Detailed description

does not involve random selection

Conditions

• Parkinson's Disease
• Hyperprolactinemia

Interventions

Type	Name	Description
DRUG	Study Drug	non interventional study - usage as per usual care

Timeline

• Start date: 2010-11-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2011-01-05
• Last updated: 2014-05-02
• Results posted: 2014-03-24